1. Home
  2. MNMD vs ETD Comparison

MNMD vs ETD Comparison

Compare MNMD & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • ETD
  • Stock Information
  • Founded
  • MNMD 2019
  • ETD 1932
  • Country
  • MNMD United States
  • ETD United States
  • Employees
  • MNMD N/A
  • ETD N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • ETD Home Furnishings
  • Sector
  • MNMD Health Care
  • ETD Consumer Discretionary
  • Exchange
  • MNMD Nasdaq
  • ETD Nasdaq
  • Market Cap
  • MNMD 709.9M
  • ETD 763.7M
  • IPO Year
  • MNMD N/A
  • ETD 1993
  • Fundamental
  • Price
  • MNMD $9.61
  • ETD $29.63
  • Analyst Decision
  • MNMD Strong Buy
  • ETD Hold
  • Analyst Count
  • MNMD 7
  • ETD 2
  • Target Price
  • MNMD $24.71
  • ETD $30.00
  • AVG Volume (30 Days)
  • MNMD 1.1M
  • ETD 291.6K
  • Earning Date
  • MNMD 11-06-2025
  • ETD 10-29-2025
  • Dividend Yield
  • MNMD N/A
  • ETD 6.21%
  • EPS Growth
  • MNMD N/A
  • ETD N/A
  • EPS
  • MNMD N/A
  • ETD 2.01
  • Revenue
  • MNMD N/A
  • ETD $614,649,000.00
  • Revenue This Year
  • MNMD N/A
  • ETD $1.12
  • Revenue Next Year
  • MNMD N/A
  • ETD $3.79
  • P/E Ratio
  • MNMD N/A
  • ETD $14.49
  • Revenue Growth
  • MNMD N/A
  • ETD N/A
  • 52 Week Low
  • MNMD $4.70
  • ETD $24.55
  • 52 Week High
  • MNMD $11.02
  • ETD $33.77
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 53.63
  • ETD 51.24
  • Support Level
  • MNMD $8.70
  • ETD $28.56
  • Resistance Level
  • MNMD $10.04
  • ETD $30.11
  • Average True Range (ATR)
  • MNMD 0.50
  • ETD 0.59
  • MACD
  • MNMD 0.00
  • ETD -0.05
  • Stochastic Oscillator
  • MNMD 73.88
  • ETD 47.10

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About ETD Ethan Allen Interiors Inc.

Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.

Share on Social Networks: